Subscribe To
MOLN / Why Molecular Partners Shares Are Getting Hammered
MOLN News
By GlobeNewsWire
November 2, 2023
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ( more_horizontal
By GlobeNewsWire
June 27, 2023
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targ more_horizontal
By GlobeNewsWire
June 19, 2023
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage more_horizontal
By GlobeNewsWire
May 25, 2023
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation more_horizontal
By GlobeNewsWire
May 16, 2023
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage b more_horizontal
By Seeking Alpha
April 20, 2023
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero. more_horizontal
By GlobeNewsWire
April 14, 2023
Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stag more_horizontal
By Seeking Alpha
March 10, 2023
Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript
Molecular Partners AG (NASDAQ:MOLN ) Q4 2022 Earnings Conference Call March 10, 2023 8:00 AM ET Company Participants Seth Lewis - Senior Vice Presiden more_horizontal